Zine News

Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib

Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen supports opening Phase 2
Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen supports opening Phase 2

Publicaciones relacionadas

Botón volver arriba
Cerrar